MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset ...

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will ...

This East Bay molecular diagnostics company shunned the traditional IPO route to go public on the market's first trading day of 2016. Its stock jumped on its first day of trading on Monday. An East ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today ...

ALAMEDA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex: BTX) and XenneX, Inc. today announced the inclusion of cell identification data in GeneCards® 3.07 available at ...